|Bid||308.53 x 300|
|Ask||311.88 x 300|
|Day's Range||309.19 - 312.23|
|52 Week Range||246.71 - 329.90|
|PE Ratio (TTM)||10.78|
|Expense Ratio (net)||0.47%|
Frazier said the experience showed him "why there can be no fair and consistent application of the death penalty under the current system."
Shares of biotech giant Amgen, Inc. (NASDAQ:AMGN), while higher by roughly 19% for the year, also remains a pain trade for momentum-chasing traders as well as longer-term investors. The broader large-cap biotech space as represented by the iShares Nasdaq Biotechnology Index (ETF) (NASDAQ:IBB) is also higher by around 18% for the year, which is to say that AMGN stock in terms of performance is trading just about in line with its peers, on average. All else being equal, this would thus also mean that AMGN stock stands a good chance of continuing to trade with this correlation to the IBB ETF.
Bullish chart patterns on key biotech names are presenting traders with the best risk/reward setup of 2017.